Charles River Laboratories CRL

Charles River Laboratories continues to face significant financial challenges, reporting mixed results for Q1 2026. While revenues reached $995.8 million, exceeding expectations, a 1.5% year-over-year decline in organic revenue and decreased adjusted earnings per share (EPS) indicate ongoing struggles. The company's recent history includes a significant net loss in Q4 2025 and a troubling net income in previous periods, leading to a cautious forecast for 2026 amid pressures on profit margins and escalating debt concerns, despite strategic moves like a $200 million stock buyback and a recent MOU with MEDIPOST to strengthen their market position.